Posts

Posted on

ProMOS Adopts Silvaco Victory TCAD Solution for the Development of Next-Gen Silicon Photonics Devices

SANTA CLARA, Calif., April 02, 2025 (GLOBE NEWSWIRE) — Silvaco Group, Inc. (Nasdaq: SVCO) (“Silvaco” or the “Company”), a provider of TCAD, EDA software and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation, today announced that ProMOS Technologies has adopted Silvaco’s Victory TCAD™ simulation solution to accelerate the development of next-generation silicon photonics devices. By leveraging Silvaco’s cutting-edge technology, ProMOS aims to enhance the accuracy, efficiency, and reliability of its photonic device designs.

Silvaco’s Victory Process™ is a comprehensive and technology-agnostic simulation solution that enables precise modeling of real-world fabrication steps, including etching, deposition, oxidation, implantation, and diffusion. Unlike simple emulation tools, Victory Process provides a detailed and accurate representation of semiconductor manufacturing, ensuring that simulated outcomes closely match actual production processes.

The Victory TCAD solution supports a wide range of cutting-edge applications, including Photonics, CMOS, Power, Memory, and Display technologies. Its user-friendly interface, automation capabilities, and advanced simulation features allow for efficient process optimization, rapid design iteration, and robust Design of Experiments (DoE) implementation. With Victory TCAD, ProMOS gains a powerful platform for accelerating innovation and refining the performance of its photonic devices.

“The adoption of Silvaco’s Victory TCAD tools marks a significant step forward for ProMOS in developing next-gen photonic devices,” said Lynn Lin, Vice President at ProMOS. “Silvaco’s product leadership, service, and technical support were instrumental in our decision to select Silvaco for our photonic device development, helping us accelerate the pace of our innovation.”

“The adoption of the Victory TCAD solution by ProMOS highlights the growing demand for advanced simulation solutions in silicon photonics,” said Eric Guichard, Senior Vice President and General Manager of the TCAD business unit at Silvaco. “We are thrilled to support ProMOS in their silicon photonics development journey. Victory TCAD provides a comprehensive simulation environment that enables companies like ProMOS to take into account process variation to optimize device performance while exploring new frontiers in photonics and semiconductor innovation.”

About Silvaco

Silvaco is a provider of TCAD, EDA software, and SIP solutions that enable semiconductor design and AI through software and innovation. Silvaco’s solutions are used for process and device development across display, power devices, automotive, memory, high performance compute, photonics, internet of things, and 5G/6G mobile markets for complex SoC design. Silvaco is headquartered in Santa Clara, California and has a global presence with offices located in North America, Europe, Brazil, China, Japan, Korea, Singapore, and Taiwan.

Contacts

Media Relations:
Tiffany Behany, [email protected]

Investor Relations:
Greg McNiff, [email protected]



Posted on

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer’s disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs.

“We are encouraged by the FDA’s Fast Track designation for BIIB080, which highlights the urgent need for innovative treatments targeting tau pathology in Alzheimer’s disease,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. “Alzheimer’s is a complex and fatal disease that we believe will require multiple therapeutic approaches to address its diverse pathologies. BIIB080, an investigational antisense therapy, is a differentiated approach to targeting tau, with promising potential for patients. We are advancing this program with urgency on behalf of people living with Alzheimer’s and their families.”

BIIB080 is the first tau-targeting ASO to enter clinical development for Alzheimer’s disease and is currently being evaluated in the global Phase 2 CELIA study in individuals with early-stage disease. As previously announced, results from the Phase 1b study showed dose-dependent reductions in soluble tau protein in cerebrospinal fluid (CSF), decreases in aggregated tau pathology in the brain as measured by positron emission tomography (PET), and favorable trends in exploratory clinical outcomes, supporting the potential for clinical benefit. In the high-dose groups, favorable trends were observed across multiple exploratory measures of cognition and function. The Phase 2 CELIA study is now fully enrolled, with a data readout expected in 2026.

About BIIB080

BIIB080 is an investigational antisense oligonucleotide (ASO) therapy designed to target microtubule-associated protein tau (MAPT) mRNA to reduce the production of tau protein. Abnormal accumulation of tau in the brain is a hallmark of Alzheimer’s disease and is associated with neurodegeneration and cognitive decline. BIIB080 is currently being evaluated in a Phase 2 clinical study (NCT05399888) in individuals with early Alzheimer’s disease.

In December 2019, Biogen exercised a license option with Ionis Pharmaceuticals and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB080 (tau ASO).

About Biogen

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

We routinely post information that may be important to investors on our website at www.biogen.com. Follow us on social media – Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor

This news release contains forward-looking statements, including about the potential clinical effects of BIIB080; the potential benefits, safety and efficacy of BIIB080; potential regulatory discussions, submissions and approvals and the timing thereof; the treatment of Alzheimer’s disease; the potential of Biogen’s commercial business and pipeline programs, including BIIB080; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

MEDIA CONTACT:
Biogen
Jack Cox
+ 1 781 464 3260
[email protected]		 INVESTOR CONTACT:
Biogen
Tim Power
+1 781 464 2442
[email protected]



Posted on

Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET.

About Sensei Biotherapeutics 
Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment to unleash T cells against tumors. Sensei’s lead product candidate is solnerstotug, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. For more information, please visit www.senseibio.com, and follow the company on X @SenseiBio and LinkedIn.

Investor Contact:

Michael Biega
Senior Director, Investor Relations
Sensei Biotherapeutics
[email protected]

Media Contact:

Joyce Allaire
LifeSci Advisors
[email protected]



Posted on

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 11:30 a.m. ET. The Company will also be holding one-on-one investor meetings at the event.

A live webcast and replay of the fireside chat will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. is a clinical-stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential as differentiated mono and combination therapies. The lead product candidate, micvotabart pelidotin (“MICVO” formerly PYX-201), is an antibody-drug conjugate (ADC) that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component of the tumor extra-cellular matrix (ECM). MICVO has been evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors with a go-forward development focus on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) based on the strength of the HNSCC signal that emerged. MICVO is designed to generate a multi-pronged attack on difficult-to-treat cancers by directly killing cancer cells, reducing ECM density, inhibiting tumor angiogenesis and mobilizing an anti-tumor immune response.

To learn more, visit www.pyxisoncology.com or follow us on X (formerly known as Twitter) and LinkedIn.

Pyxis Oncology Contact

Pamela Connealy
CFO and COO
[email protected]



Posted on

XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference

EMERYVILLE, Calif., April 02, 2025 (GLOBE NEWSWIRE) — XOMA Royalty Corporation (“XOMA”; NASDAQ: XOMA), the biotech royalty aggregator, announced today Chief Investment Officer, Brad Sitko, will be a featured presenter at the Jones Healthcare and Technology Innovation Conference being held April 8-9, 2025.

Mr. Sitko’s presentation will take place on Wednesday, April 9, 2025, at 10:30 AM PT.  The presentation can be assessed by visiting https://bit.ly/4l7bz6m.

XOMA’s presentations can also be accessed by visiting the investor relations section of the Company’s website at www.xoma.com.  A replay of each presentation will be available and archived on the site for 90 days after the event.

About XOMA Royalty Corporation

XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health.  XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies.  When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes.  The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate).  For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.

XOMA Investor Contact

Juliane Snowden
XOMA Royalty
+1 646-438-9754
[email protected]		 XOMA Media Contact

Kathy Vincent
KV Consulting & Management
[email protected]



Posted on

Kforce Inc. to Announce First Quarter Results on April 28, 2025

Kforce Inc. to Announce First Quarter Results on April 28, 2025

TAMPA, Fla.–(BUSINESS WIRE)–
Kforce Inc. (NYSE: KFRC), a provider of professional staffing services and solutions, will release first quarter results post-market on Monday, April 28, 2025, followed by a conference call at 5:00 pm ET to discuss the results. The dial-in number is (800) 715-9871 and the conference passcode is “Kforce”. A replay of the call will be available on our website at https://investor.kforce.com for one year after the call.

About Kforce Inc.

Kforce Inc. (the “Firm”) is a solutions firm specializing in technology, finance and accounting, and other professional staffing services. Our KNOWLEDGEforce® empowers industry-leading companies to achieve their digital transformation goals. We curate teams of technical experts who deliver solutions custom-tailored to each client’s needs. These scalable, flexible outcomes are shaped by deep market knowledge, thought leadership and our multi-industry expertise.

Our integrated approach is rooted in 60 years of proven success deploying highly skilled professionals on a temporary and direct-hire basis. Each year, approximately 18,000 talented experts work with Fortune 500 and other leading companies. Together, we deliver Great Results Through Strategic Partnership and Knowledge Sharing®.

Cautionary Note Regarding Forward-Looking Statements

All statements in this press release, other than those of a historical nature, are forward-looking statements including, but not limited to, statements regarding the backlog of desired investments that are expected to be high priorities once the macro uncertainties begin to clear, the evolution and increasingly instrumental role of technology in driving businesses, demand drivers of technology spend, the acceleration of technological change, the Firm’s confidence in being well positioned for improving market conditions, and the Firm’s quarterly guidance. Such forward-looking statements are within the meaning of that term in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Factors that could cause actual results to differ materially include the following: business conditions; growth rate in temporary staffing and the general economy; competitive factors; risks due to shifts in the market demand; changes in client demand or our ability to adapt to such changes; a constraint in the supply of consultants and candidates or the Firm’s ability to attract and retain such individuals; the success of the Firm in attracting and retaining its management team and key operating employees; changes in business or service mix; the ability of the Firm to repurchase shares; the occurrence of unanticipated expenses, income, gains or losses; the effect of adverse weather conditions; changes in our effective tax rate; our ability to comply with government regulations, laws, orders, guidelines and policies that impact our business; risk of contract performance, delays, termination or the failure to obtain new assignments or contracts, or funding under contracts; ability to comply with our obligations in a remote work environment; continued performance and security of, and improvements to, our enterprise information systems; impacts of actual or potential litigation or other legal or regulatory matters or liabilities, including the risk factors and matters listed from time to time in the Firm’s reports filed with the Securities and Exchange Commission, including, but not limited to, the Firm’s Form 10-K for the fiscal year ended December 31, 2024, as well as assumptions regarding the foregoing. The terms “should,” “believe,” “estimate,” “expect,” “intend,” “anticipate,” “plan” and similar expressions and variations thereof contained in this press release identify certain of such forward-looking statements, which speak only as of the date of this press release. As a result, such forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Future events and actual results may differ materially from those indicated in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements and the Firm undertakes no obligation to update any forward-looking statements.

Michael R. Blackman, Chief Corporate Development Officer

(813) 552-2927

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Finance Accounting Professional Services Fintech Human Resources

MEDIA:

Logo
Logo
Posted on

Redwire Appoints Mike Gold as President of Civil and International Space Business to Lead Global Expansion

Redwire Appoints Mike Gold as President of Civil and International Space Business to Lead Global Expansion

JACKSONVILLE, Fla.–(BUSINESS WIRE)–
Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next-generation space economy, today announced that Mike Gold has been appointed President of Civil and International Space business.

This key appointment emphasizes the company’s focus on scaling global growth and accessing additional international market sectors. Redwire recently expanded its European footprint by opening a new office in Warsaw, Poland. With institutional space budgets (civil and defense) across global spacefaring nations collectively reaching record highs in recent years and the European Space Agency (ESA) committed to ensuring sustainable growth in the European space sector, Redwire is well positioned to grow its civil and international business.

“We are very pleased to appoint Mike to this new role within the company as we continue to scale our business internationally. Mike is a well-known space leader with the international experience and global relationships to meet our strategic goals,” said Peter Cannito, Redwire Chairman and CEO. “With a significant international presence and proven performance on orbit with multiple Proba satellites and other critical European programs, Redwire is well positioned for global growth under Mike’s leadership.”

About Mike Gold

Prior to joining Redwire, Gold was NASA’s Associate Administrator for Space Policy and Partnerships, Acting Associate Administrator for the Office of International and Interagency Relations, and Senior Advisor to the Administrator for International and Legal Affairs. Gold was awarded NASA’s Outstanding Leadership Medal in recognition for his achievements while at NASA including the Artemis Accords, the Gateway MOUs, and regulatory reforms. Before joining NASA, Gold was Vice President of Civil Space at Maxar Technologies, General Counsel for the company’s legacy Radiant Solutions business unit, and Vice President of Washington Operations and Business Development. Gold also spent 13 years at Bigelow Aerospace where he established the company’s Washington office, oversaw the launches of the Genesis 1 and 2 spacecraft, and was a recipient of a NASA Group Achievement award for the development and deployment of the Bigelow Expandable Activity Module (BEAM) on the International Space Station. Additionally, Gold received the International Astronautical Federation’s 2024 Excellence in International Cooperation Award, a 2025 Aviation Week Laureate Award for the Artemis Accords, and a 2024 NASA Silver Group Achievement Award for his role on the agency’s UAP Independent Study Team. Gold has served as Chair of the Department of Transportation’s Commercial Space Transportation Advisory Committee, Chair of the NASA Advisory Committee’s Regulatory and Policy Committee, and was a member of the National Academies Space Technology Industry-Government-University Roundtable. Gold has authored numerous law review articles and editorials addressing commercial space issues. He has also testified on many occasions before the U.S. House of Representatives and the U.S. Senate as an expert in commercial space as well as space law and policy. Gold received a BA from Brandeis University and a JD from the University of Pennsylvania Law School.

About Redwire

Redwire Corporation (NYSE: RDW) is a global space infrastructure and innovation company enabling civil, commercial, and national security programs. Redwire’s proven and reliable capabilities include avionics, sensors, power solutions, critical structures, mechanisms, radio frequency systems, platforms, missions, and microgravity payloads. Redwire combines decades of flight heritage and proven experience with an agile and innovative culture. Redwire’s approximately 750 employees working from 17 facilities located throughout the United States and Europe are committed to building a bold future in space for humanity, pushing the envelope of discovery and science while creating a better world on Earth. For more information, please visit redwirespace.com.

Media Contact:

Tere Riley

[email protected]

321-831-0134

OR

Investors:

[email protected]

904-425-1431

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Satellite Technology Aerospace Manufacturing Other Technology Other Science Science

MEDIA:

Logo
Logo
Posted on

Canopy Growth and Spectrum Therapeutics Announce Spectrum Reserve, A New Premium Medical Cannabis Brand

Canopy Growth and Spectrum Therapeutics Announce Spectrum Reserve, A New Premium Medical Cannabis Brand

New Brand Features Premium Genetics, Selected for Potency, Terpenes, and Consistency

SMITHS FALLS, Ontario–(BUSINESS WIRE)–
Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has launched Spectrum Reserve, a new premium medical cannabis brand in Canada. Designed to meet the evolving needs of medical cannabis patients, Spectrum Reserve represents the peak of cannabis cultivation – featuring flower selected for size, potency, and terpene levels through rigorous in-house standards during cultivation and post-harvest.

Under this new program, Spectrum Reserve is expected to introduce new strains on a regular basis based on patient needs, preferences, and feedback. The strains which generate the most positive and consistent customer feedback will remain in market, while others will be phased out to make way for new genetics through a process of constant enhancement. This approach will help Spectrum Therapeutics consistently deliver new, premium quality strains to the medical cannabis market in Canada.

“By selecting only the genetics that deliver an elevated combination of THC and terpenes, Spectrum Reserve offers a cannabis experience that evolves through continuous innovation while consistently meeting the needs of medical cannabis patients,” said Andrew Bevan, SVP Medical Sales, Canopy Growth. “This new Spectrum Reserve program reinforces our leadership in medical cannabis by combining industry-leading cultivation with a strong focus on premium quality.”

The first release under the Spectrum Reserve brand features four flower strains, each selected for the combination of their potency and terpene profile:

  1. Power Plant x Super Silver Haze (Indica, 22-25% THC): A rich, woody and earthy aroma, with a sharp, peppery taste and 2.21% total terpenes.
  2. Grape Star x Golden Lemons (Sativa, 22-25% THC): With a dank white grape aroma, this strain features 1.77% total terpenes, offering a smooth, uplifting experience.
  3. Malawi x Kosher Tangie (Hybrid, 27-30% THC): A complex citrus and chocolate flavour profile, complemented by a pungent, earthy aroma, with 2.59% total terpenes.
  4. Raspberry Parfait (Sativa-Dominant Hybrid, 22-27% THC): With 2.59% total terpenes, this strain features a plum, berry, and violet aroma for a rich and flavorful experience.

Patients registered with Spectrum Therapeutics can visit www.spectrumtherapeutics.com to obtain more information on Spectrum Reserve flower strains.

About Canopy Growth

Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives.

Through an unwavering commitment to our consumers, Canopy Growth delivers innovative products with a focus on premium and mainstream cannabis brands including Tweed, 7ACRES, DOJA, Deep Space and Claybourne, as well as category-defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Europe and Australia.

Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA. Canopy USA’s portfolio includes ownership of Acreage Holdings, a vertically integrated multi-state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Brands, a leading North American edibles brand, and majority ownership of Jetty Extracts, a California-based producer of high-quality cannabis extracts and clean vape technology.

At Canopy Growth, we’re shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we’re paving the way for a better understanding of all that cannabis can offer.

For more information visit www.canopygrowth.com.

More Information

Alex Thomas

Director, Communications

[email protected]

Investor Contact:

Tyler Burns

Director, Investor Relations

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Alternative Medicine Cannabis Retail Health Specialty Natural Resources

MEDIA:

Logo
Logo
Posted on

Bowman Awarded $2.2M Contract for ADA Design in Philadelphia

Bowman Awarded $2.2M Contract for ADA Design in Philadelphia

Award marks Bowman’s fifth consecutive ADA-related contract for pedestrian infrastructure enhancements in the city

RESTON, Va.–(BUSINESS WIRE)–
Bowman Consulting Group Ltd. (NASDAQ: BWMN), a national engineering services firm, has been awarded a $2.2 million contract to design 1,236 ADA-compliant curb ramps at 355 intersections across the City of Philadelphia. This contract marks the fifth consecutive ADA-related assignment Bowman has undertaken in Philadelphia and aligns with the city’s broader initiative to install 10,000 ADA-compliant curb ramps by April 2038.

Under this new assignment, Bowman will provide comprehensive ADA design services, overseeing the engineering and design of curb ramps in compliance with PennDOT and City of Philadelphia standards, while also conducting right-of-way (ROW) assessments to ensure the designs remain within public property limits. As part of the contract, Bowman’s scope of work includes evaluating existing site conditions, developing alternative ramp configurations as needed, facilitating property owner coordination, addressing historic review requirements and providing ongoing design-related guidance throughout the project.

“Bowman is proud to support Philadelphia’s commitment to accessibility by designing thousands of ADA-compliant curb ramps and transit solutions across the city,” said Gary Bowman, chairman and CEO of Bowman. “Under our previous four contracts, we’ve delivered or are in the process of delivering 3,480 curb ramps at 920 intersections, with a combined value exceeding $5.1 million. Under this new contract and in anticipation of additional ADA ramp contracts expected from the city in the coming years, Bowman is well-positioned to continue enhancing Philadelphia’s pedestrian infrastructure in support of its long-term accessibility goals.”

Bowman’s expertise in ADA-compliant infrastructure extends across the country, supporting municipalities of all sizes in their mission to improve pedestrian accessibility. With a portfolio spanning thousands of curb ramps and transit solutions, Bowman has consistently demonstrated a comprehensive understanding of the challenges and intricacies involved in designing accessible public spaces. As communities nationwide prioritize more inclusive pedestrian networks, Bowman continues to lead the way, delivering practical solutions that enhance mobility for all.

About Bowman Consulting Group Ltd.

Headquartered in Reston, Virginia, Bowman is a national engineering services firm delivering infrastructure, technology and project management solutions to customers who own, develop and maintain the built environment. With over 2,300 employees in more than 100 locations throughout the United States, Bowman provides extensive planning, engineering, geospatial, construction management, commissioning, environmental consulting, land procurement and other technical services to customers operating in a diverse set of regulated end markets. Bowman trades on the Nasdaq under the symbol BWMN. For more information, visit bowman.com or investors.bowman.com.

General Media Contact:

Christina Nichols

[email protected]

Investor Relations Contact:

Betsy Patterson

[email protected]

KEYWORDS: United States North America Pennsylvania Virginia

INDUSTRY KEYWORDS: Engineering Consumer Other Construction & Property Manufacturing Construction & Property Urban Planning People with Disabilities

MEDIA:

Logo
Logo
Posted on

Aramark’s IN2WORK Job Skills Program Turns 20:Educational Path in Correctional Facilities Has Grown to 32 States, more than 290 Programs, and more than 14,000 Graduates

Aramark’s IN2WORK Job Skills Program Turns 20:

Educational Path in Correctional Facilities Has Grown to 32 States, more than 290 Programs, and more than 14,000 Graduates

PHILADELPHIA–(BUSINESS WIRE)–
Aramark Correctional Services is celebrating the 20th anniversary of its IN2WORK (I2W) program, a milestone in the journey of working with thousands of justice-impacted individuals, offering education and industry certifications for a path to success both during and post-incarceration.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250402392828/en/

Aramark Correctional Services is celebrating the 20th anniversary of its IN2WORK (I2W) program, a milestone in the journey of working with thousands of justice-impacted individuals, offering education and industry certifications for a path to success both during and post-incarceration.

Aramark Correctional Services is celebrating the 20th anniversary of its IN2WORK (I2W) program, a milestone in the journey of working with thousands of justice-impacted individuals, offering education and industry certifications for a path to success both during and post-incarceration.

The opt-in IN2WORK program helps incarcerated people prepare for careers and re-entry into their communities by offering food and warehouse safety training—ServSafe Managers certification from the National Restaurant Association, and a Certified Specialist certificate from the National Retail Federation in Supply Chain, Inventory & Logistics, respectively—through both classroom and hands-on-training, taking a phased approach to learning.

“We are part of the lives of many justice-impacted people every day through our food and commissary operations, which provides us with a unique opportunity to affect change and offer hope of new beginnings,” said Tim Barttrum, President and CEO of Aramark Correctional Services. “We always look for opportunities to make a difference, and IN2WORK does just that, and it has been a privilege to see it grow from a feature we offered to an integral part of our mission.”

IN2WORK had its genesis in 1999 with a goal of providing incarcerated individuals with food safety training and experience working in a team environment. During the program’s first decade, it became more formalized, gained the IN2WORK moniker, and expanded from food to retail and warehousing training. Since its launch, I2W has been implemented in 32 states, with more than 290 programs, and has graduated more than 14,000 students.

Promoting Post Release Success

The goal of I2W is to help incarcerated individuals take control of their lives by giving them the tools, experience, certifications, and confidence they need to support themselves and their families as they transition back to life in their communities. Graduates of the I2W program, as well as their family members, are eligible for Aramark scholarships to help them complete their educational goals. In the last five years, more than $170K has been awarded to graduates and their families.

“There is growing recognition that incarceration alone is not an effective solution to reducing recidivism and that there is power in education and employment for rehabilitation and helping break the cycle of incarceration,” said Nicole McVaugh, Director of the IN2WORK program. “Reentry is a place where small victories can make a big difference. Whether it’s implementing mentorship programs, forging partnerships with community organizations, or expanding job training initiatives, the program expansion and success of our graduates is a priority.”

The Program and Student Evolution

The program has resonated with facility residents, thousands of whom have opted into I2W and using the program as a stepping-stone to their futures. Aramark Correctional Services consistently see results with those who implement the program, including increased self-worth, esteem, and morale among the residents, factors that have been proven to promote a safer environment and more positive outcomes for those who are incarcerated.

“The IN2WORK impact has reached beyond what any of us had every thought it would. The goals in the beginning were simple: provide food safety education to those incarcerated,” said Belinda Peterson, IN2WORK Manager. “Additionally, we listened to the needs of our graduates that have been released, and we realized that job placement was a huge need. Aramark is a Fair Chance company because it’s the right thing to do. We started this path 20 years ago and we provide so much more than a book and a certification. Our IN2WORK program gives hope—hope for a better future for themselves, their families, and their communities.”

About Aramark Correctional Services

Aramark Correctional Services offers efficient, safe, and nutritious hospitality experiences to correctional staff and justice-impacted individuals by providing stellar food and commissary services that contribute to a secure environment. Whether facilitating family connections or teaching essential career skills like warehouse operations, hospitality, and management, Aramark Correctional Services empowers justice-impacted individuals to re-establish their place in society through the IN2WORK® program, providing individuals with skills necessary for successful reintegration. Connect with Correctional Services on LinkedIn to learn more.

About Aramark

Aramark (NYSE: ARMK) proudly serves the world’s leading educational institutions, Fortune 500 companies, world champion sports teams, prominent healthcare providers, iconic destinations and cultural attractions, and numerous municipalities in 16 countries around the world with food and facilities management. Because of our hospitality culture, our employees strive to do great things for each other, our partners, our communities, and the planet. Learn more at www.aramark.com and connect with us on LinkedIn, Facebook, X, and Instagram.

Heather Dotchel, [email protected]

KEYWORDS: United States North America Pennsylvania

INDUSTRY KEYWORDS: Other Retail Professional Services Philanthropy Food/Beverage Other Education Continuing Other Philanthropy Retail Education Other Professional Services

MEDIA:

Photo
Photo
Aramark Correctional Services is celebrating the 20th anniversary of its IN2WORK (I2W) program, a milestone in the journey of working with thousands of justice-impacted individuals, offering education and industry certifications for a path to success both during and post-incarceration.
Logo
Logo